General Information of Drug Combination (ID: DC3T71J)

Drug Combination Name
DFN-15 Taxol
Indication
Disease Entry Status REF
Renal cell carcinoma Investigative [1]
Component Drugs DFN-15   DM3BF9B Taxol   DMUOT9V
N.A. Small molecular drug
High-throughput Screening Result Testing Cell Line: UO-31
Zero Interaction Potency (ZIP) Score: 0.14
Bliss Independence Score: 5.52
Loewe Additivity Score: 2.82
LHighest Single Agent (HSA) Score: 3.9

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of DFN-15
Disease Entry ICD 11 Status REF
Migraine 8A80 Phase 3 [2]
Indication(s) of Taxol
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [3]
Solid tumour/cancer 2A00-2F9Z Approved [4]
Pancreatic cancer 2C10 Phase 3 [5]
Gastric adenocarcinoma 2B72 Phase 2 [6]
Ovarian cancer 2C73 Phase 2 [6]
Taxol Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Apoptosis regulator Bcl-2 (BCL-2) TTJGNVC BCL2_HUMAN Modulator [3]
Tubulin beta (TUBB) TTYFKSZ NOUNIPROTAC Modulator [3]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Astrocytoma DCPI08Q U251 Investigative [1]
Clear cell renal cell carcinoma DCSNZAC 786-0 Investigative [1]
Clear cell renal cell carcinoma DCGNPDY A498 Investigative [1]
Glioblastoma DCSXDDC SNB-75 Investigative [1]
Glioma DCB0A4D SF-268 Investigative [1]
Glioma DC9MBVJ SF-295 Investigative [1]
Breast adenocarcinoma DCRKTDX MDA-MB-468 Investigative [7]
Colon carcinoma DCOOPCN KM12 Investigative [7]
Invasive ductal carcinoma DCI1ARZ BT-549 Investigative [7]
Adenocarcinoma DC0J66X HT29 Investigative [8]
Large cell lung carcinoma DCL1G2S NCI-H460 Investigative [8]
Lung adenocarcinoma DCFSRKM MDA-MB-231 Investigative [8]
Mixed endometrioid and clear cell carcinoma DCJCY6M IGROV1 Investigative [8]
Ovarian serous cystadenocarcinoma DC7IV5F SK-OV-3 Investigative [8]
Prostate carcinoma DCOMFQQ PC-3 Investigative [8]
------------------------------------------------------------------------------------
⏷ Show the Full List of 15 DrugCom(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
8 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.